New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
06:31 EDTARIAFoundation Medicine, ARIAD announce collaboration to study AP26113
Foundation Medicine and ARIAD announced a genomic profiling collaboration to study AP26113, ARIAD's investigational dual-inhibitor of ALK and EGFR in patients with non-small cell lung cancer and other cancers. Foundation Medicine will work with ARIAD to generate genomic profile information for patients enrolled in ARIAD's ongoing Phase 1/2 trial and these data will be matched with clinical observations to understand the activity and selectivity profile of AP26113.
News For ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
07:37 EDTARIAARIAD announces data presentations at EHA Congress
Subscribe for More Information
May 20, 2015
10:29 EDTARIAOptions with decreasing implied volatility
Options with decreasing implied volatility: ZIOP KING ARIA CTRP WTW VHC XON KERX VIPS JCP
May 19, 2015
11:59 EDTARIAOptions with decreasing implied volatilit
Subscribe for More Information
May 18, 2015
10:37 EDTARIAOptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP ZIOP CLNE ARIA VHC AOL KING XON PEIX
May 14, 2015
08:04 EDTARIAARIAD to present data on Iclusig, brigatinib at ASCO meeting
Subscribe for More Information
May 12, 2015
07:52 EDTARIALeerink to hold a tour
Subscribe for More Information
May 8, 2015
08:49 EDTARIAARIAD price target raised to $11 from $8 at JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use